UT researcher: Interferon alpha can delay full onset of type I diabetes
A low dose of oral interferon alpha shows promise in preserving beta cell function for patients with newly diagnosed type 1 diabetes, or juvenile diabetes, according to researchers at The University of Texas Medical School at Houston. The results of the Phase II trial are published today in Diabetes Care, a journal of the American Diabetes Association.
"It shows a strong trend in preserving insulin-producing beta cell function that is significantly better than placebo," said Staley Brod, M.D., principal investigator of the trial, which includes the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "It can extend the 'honeymoon phase' of the disease, allowing the body to still produce insulin from beta cells, which correlates with decreased complication rates."
As many as 3 million Americans may have type I diabetes, formerly called juvenile diabetes, according to the Juvenile Diabetes Research Foundation International. Each year, 15,000 children are diagnosed with the autoimmune disease, in which the pancreas stops producing the insulin needed to transfer glucose from the blood to cells for energy. The result is too much glucose in the blood, which can lead to kidney failure, blindness, nerve damage, amputations, heart attack and stroke.
A honeymoon phase sometimes occurs just after diagnosis as the body tries to rebound. Many patients experience a period when their need for insulin becomes minimal, control of blood sugar improves and beta cells partially recover. If the pancreas is still able to function, the highs and lows experienced by taking manufactured insulin can be decreased.
The Phase II trial included 128 patients from the NIDDK's Intramural Studies Office, The University of Texas Southwestern Medical Center in Dallas and Children's Hospitals and Clinics in Minneapolis/St. Paul, Minn. Research was conducted at The University of Texas Clinical Research Center at Memorial Hermann-Texas Medical Center, which is part of the Center for Clinical and Translational Sciences at The University of Texas Health Science Center at Houston.
Research subjects ages 3 to 25 diagnosed with type 1 diabetes within six weeks of enrollment were randomized to receive 5,000 units of interferon alpha, 30,000 units of interferon alpha or placebo once daily for one year. Patients treated with 5,000 units lost only 29 percent of their beta cell function compared to 48 percent for patients receiving 30,000 units and 56 percent for patients receiving the placebo.
Austin resident Jarod Wallquist, 11, was 5 years old when he was diagnosed with type I diabetes and his mother Amy learned about Brod's study. Jarod received the 5,000 units of interferon alpha, but neither she nor the researchers knew it at the time because of the double-blind nature of the study.
"My husband and I are both scientific-minded so we understood the importance of the research even if we didn't know whether it would help Jarod," said Wallquist, whose family made regular trips to Houston for the study. "Jarod is doing really well. He wears an insulin pump but he's never had to go to the emergency room. To this day, according to his doctor, his amount of insulin needed is much lower than other kids his age and weight. He plays baseball and is on the swim team and he totally has a normal life."
The research builds on Brod's earlier studies on oral interferon alpha in animals and a Phase I safety trial. After the results of the safety trial, NIDDK researchers asked to join Brod's research before the Phase II trial.
Brod's theory is that autoimmune diseases, which occur when the body is attacked by its own immune system, are actually an alpha interferon immunodeficiency syndrome. Interferons are a group of proteins produced by cells in response to an attack by a virus.
- USC researchers present diabetes findings at American Diabetes Association Scientific SessionsFri, 5 Jun 2009, 9:50:53 EDT
- Diabetes weakens your bonesMon, 28 Sep 2009, 16:08:20 EDT
- New scientific knowledge on juvenile diabetesWed, 17 Dec 2008, 11:37:00 EST
- Researchers show some cells in pancreas can spontaneously change into insulin-producing cellsMon, 5 Apr 2010, 8:57:46 EDT
- Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trialSun, 26 Jun 2011, 22:33:31 EDT
- UT researcher: Interferon alpha can delay full onset of type I diabetesfrom Biology News NetWed, 1 Jul 2009, 18:49:32 EDT
- Interferon alpha can delay full onset of type 1 diabetesfrom Science CentricWed, 1 Jul 2009, 14:00:19 EDT
- Interferon Alpha Can Delay Full Onset Of Type I Diabetes, Phase II Trial Suggestsfrom Science DailyWed, 1 Jul 2009, 9:35:19 EDT
- Interferon alpha can delay full onset of type I diabetesfrom PhysorgWed, 1 Jul 2009, 9:21:03 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- 2 miniature spider species discovered in Giant Panda Sanctuaries of China
- Researchers reveal model of Sun's magnetic field
- The Norway spruce genome sequenced
- UCLA life scientists present new insights on climate change and species interactions
- Bacterial spare parts filter antibiotic residue from groundwater
- Allosaurus fed more like a falcon than a crocodile, new study finds
- Invasive crazy ants are displacing fire ants in areas throughout southeastern US
- Beautiful 'flowers' self-assemble in a beaker
- Scientific insurgents say 'Journal Impact Factors' distort science
- GPS solution provides 3-minute tsunami alerts